Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM1PRT6)

• Drug Name: M710 Drug Info
• Synonyms: 637-01-4; N,N,N',N'-Tetramethyl-p-phenylenediamine dihydrochloride; N1,N1,N4,N4-tetramethylbenzene-1,4-diamine dihydrochloride; N,N,N',N'-Tetramethyl-1,4-phenylenediamine Dihydrochloride; UNII-66W8HKA51X; MFCD00012482; 66W8HKA51X; tetramethyl-p-phenylenediamine dihydrochloride; 1,4-Benzenediamine, N,N,N',N'-tetramethyl-, dihydrochloride; NSC36730; 1,4-Benzenediamine, N1,N1,N4,N4-tetramethyl-, hydrochloride (1:2); 1-N,1-N,4-N,4-N-tetramethylbenzene-1,4-diamine;dihydrochloride; Wursters Reagent; N,N,N',N'-Tetramethyl-p-phenylenediamine dihydrochloride, 99%; EINECS 211-274-8; NSC 36730; TMPPD; ACMC-1B8O0; SCHEMBL379125; DTXSID2060915; N,N,N',N'-Tetramethyl-para-phenylenediamine dihydrochloride; ANW-34710; AKOS005254702; MCULE-3840175847; VZ32824; AS-14819; SY061584; 3-(4-Bromo-1H-pyrazol-1-yl)propanoicacid; DB-054526; FT-0629355; ST50308398; Tetramethyl-p-phenylene diamine hydrochloride; 1,4-Bis(dimethylamino)benzene dihydrochloride; X-4255; N,N,N',N'-Tetramethyl-p-phenylenediamine 2HCl; N,N,N',N'-Tetramethyl-p-phenylenediamine DiHCl; W-104885; Q27264036; [4-(dimethylamino)phenyl]dimethylamine, chloride, chloride; N,N,N\\',N\\'-Tetramethyl-p-phenylenediamine dihydrochloride; N1,N1,N4,N4-Tetramethyl-1,4-benzenediamine Dihydrochloride; p-Phenylenediamine, N,N,N',N'-tetramethyl-, dihydrochloride (8CI); N,N,N',N'-Tetramethyl-p-phenylenediamine dihydrochloride, >=95%, powder; N,N,N',N'-Tetramethyl-p-phenylenediamine dihydrochloride, >=97.0% (AT)

Indication

Disease Entry	ICD 11	Status	REF
Diabetic macular edema	9B71.02	Phase 3	[1]

• Cross-matching ID:
  PubChem CID: 71561
  CAS Number: CAS 637-01-4
  TTD Drug ID: DM1PRT6

Molecule-Related Drug Atlas

Drug(s) Targeting Vascular endothelial growth factor (VEGF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Brolucizumab	DMW8QNG	Wet age-related macular degeneration	9B78.3Z	Approved	[3]
Squalamine	DM3PS2E	Solid tumour/cancer	2A00-2F9Z	Phase 3	[4]
PF-06439535	DMVHZDP	Non-small-cell lung cancer	2C25.Y	Phase 3	[5]
FKB238	DM6R2XF	Non-small-cell lung cancer	2C25.Y	Phase 3	[6]
KSI-301	DMM2LTC	Diabetic macular edema	9B71.02	Phase 3	[7]
TRS003	DMM1VOH	Colorectal cancer	2B91.Z	Phase 3	[8]
MYL-1402O	DMXN2PP	Non-small-cell lung cancer	2C25	Phase 3	[9]
SB15	DMTOS6C	Neovascular age-related macular degeneration	9B78.3Z	Phase 3	[10]
Dilpacimab	DMCATH2	Solid tumour/cancer	2A00-2F9Z	Phase 2	[11]
ALG-1001	DMR2YPF	Diabetic macular edema	9B71.02	Phase 2	[12]

Drug(s) Affected By Ly6/PLAUR domain-containing protein 6 (LYPD6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[13]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[14]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[15]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[16]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[17]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[18]
Sulforaphane	DMQY3L0	Skin disease	EA00-EM0Z	Investigative	[19]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Vascular endothelial growth factor (VEGF)	TT9HKJA	VEGFA_HUMAN; VEGFB_HUMAN; VEGFC_HUMAN; VEGFD_HUMAN	Inhibitor	[1]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Ly6/PLAUR domain-containing protein 6 (LYPD6)	OTT45DF7	LYPD6_HUMAN	Drug Response	[2]

References

• [1] ClinicalTrials.gov (NCT03610646) Comparative Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea in Subjects With Diabetic Macular Edema. U.S. National Institutes of Health.
• [2] Population-based in vitro hazard and concentration-response assessment of chemicals: the 1000 genomes high-throughput screening study. Environ Health Perspect. 2015 May;123(5):458-66. doi: 10.1289/ehp.1408775. Epub 2015 Jan 13.
• [3] Brolucizumab: First Approval. Drugs. 2019 Dec;79(18):1997-2000.
• [4] Clinical pipeline report, company report or official report of Ohr Pharmaceutical.
• [5] National Cancer Institute Drug Dictionary (drug id 43234).
• [6] Clinical pipeline report, company report or official report of Fujifilm.
• [7] Clinical pipeline report, company report or official report of Kodiak Sciences.
• [8] Prevalence of porcine cysticercosis in Vellore, South India. Trans R Soc Trop Med Hyg. 2013 Jan;107(1):62-4.
• [9] MYL-1402O: A Bevacizumab Biosimilar. Target Oncol. 2022 Jan;17(1):85-88.
• [10] Efficacy and Safety of the Aflibercept Biosimilar SB15 in Neovascular Age-Related Macular Degeneration: A Phase 3 Randomized Clinical Trial. JAMA Ophthalmol. 2023 Jul 1;141(7):668-676.
• [11] Apoptogenic activity of 2alpha,3alpha-dihydroxyurs-12-ene-28-oic acid from Prunella vulgaris var. lilacina is mediated via mitochondria-dependent activation of caspase cascade regulated by Bcl-2 in human acute leukemia Jurkat T cells. J Ethnopharmacol. 2011 Jun 1;135(3):626-35.
• [12] Future therapies of wet age-related macular degeneration. J Ophthalmol. 2015;2015:138070.
• [13] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [14] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [15] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [16] Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019 Nov 15;383:114761. doi: 10.1016/j.taap.2019.114761. Epub 2019 Sep 15.
• [17] DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
• [18] From transient transcriptome responses to disturbed neurodevelopment: role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects. Arch Toxicol. 2014 Jul;88(7):1451-68.
• [19] Transcriptome and DNA methylation changes modulated by sulforaphane induce cell cycle arrest, apoptosis, DNA damage, and suppression of proliferation in human liver cancer cells. Food Chem Toxicol. 2020 Feb;136:111047. doi: 10.1016/j.fct.2019.111047. Epub 2019 Dec 12.